Ligand Pharmaceuticals | LGND - Current Liabilities


Ligand Pharmaceuticals reported $40.67M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Agenus USD 249.24M 74.25M Mar/2026
Amgen USD 24.96B 534M Mar/2026
Anika Therapeutics USD 20.97M 942K Mar/2026
Arrowhead Research USD 295.22M 52.2M Mar/2026
Baxter International USD 3.69B 723M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Enviri Corporation USD 640.69M 6.67M Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Glaxosmithkline GBP 28.82B 144.79M Dec/2025
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Insmed USD 361.01M 107.87M Mar/2026
Intrexon USD 23.02M 38K Jun/2024
Ionis Pharmaceuticals USD 717M 66M Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Ligand Pharmaceuticals USD 40.67M 3.22M Mar/2026
MacroGenics USD 95.94M 52.82M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Pacira USD 108.79M 11.8M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Veracyte USD 56.11M 3.82M Mar/2026